Tuesday, March 27, 2018

Only 5% of hepatitis B patients received antiviral therapy in 2016

In The News

HBV Treatment Fails to Meet Global Targets

by Molly Walker, Staff Writer
MedPage Today March 26, 2018

Only 5% of hepatitis B patients received antiviral therapy in 2016

Only an estimated one in 20 patients with hepatitis B worldwide received antiviral therapy for their illness in 2016, a modeling study found.

Of the estimated 292 million people living with hepatitis B virus (HBV), there were 94 million individuals eligible for treatment, but only 4.8 million (5%) actually received it, reported The Polaris Observatory Collaborators. Moreover, less than half of infants received timely birth dose vaccination, and less than 1% of mothers with a high viral load received antiviral therapy in 2016, the authors wrote in the Lancet Gastroenterology & Hepatology.

MedPage Today Full Article:

Lancet Study:
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (HBV) infection, existing therapies to control viral replication and prophylaxis to minimise mother-to-child transmission make elimination of HBV feasible. We aimed to estimate the national, regional, and global prevalence of HBsAg in the general population and in the population aged 5 years in 2016, as well as coverage of prophylaxis, diagnosis, and treatment.

No comments:

Post a Comment